Alzheimer Early Detection And Diagnosis / 阿尔茨海默病早期识别与诊断

Definition

Alzheimer early detection and diagnosis is the staged process of noticing meaningful cognitive change, screening proportionately, excluding alternative causes, and using clinical assessment plus selected biomarkers to determine whether Alzheimer disease is a plausible cause and what stage is present.

Current Synthesis

VOL.133 separates ordinary forgetfulness, subjective cognitive decline, mild cognitive impairment, and Alzheimer dementia. The important practical boundary is functional change: memory, language, attention, emotion, behavior, or familiar tasks becoming different from a person’s prior pattern should prompt assessment, but no single complaint or screening score proves Alzheimer disease.

The source describes diagnosis as a synthesis of history, cognitive testing, differential diagnosis, imaging, blood or cerebrospinal-fluid testing, and biomarkers such as Aβ, tau, and neurodegeneration indicators. Earlier recognition matters because reversible contributors may be found, planning can begin while the person can participate, and some disease-modifying treatments are intended for selected earlier-stage patients.

Key Claims

• Alzheimer disease is one dementia cause, while memory complaints have a broader differential diagnosis.
• Subjective cognitive decline, mild cognitive impairment, and dementia-level impairment should not be collapsed into one stage.
• Screening identifies possible concern; it does not replace clinical diagnosis.
• Change from prior function and interference with daily life are central reasons to seek assessment.
• Differential diagnosis matters because some cognitive problems may arise from treatable contributors.
• Biomarkers can support diagnosis and staging but remain part of a wider clinical judgment.
• Earlier assessment creates treatment and planning opportunities without guaranteeing prevention or reversal.

Evidence

• Stage distinction - VOL.133“____，您还记得我是谁吗？”请停止这样的提问,你能做的还有很多 distinguishes normal cognition, subjective decline, mild cognitive impairment, and Alzheimer dementia stages.
• Functional warning signs - VOL.133“____，您还记得我是谁吗？”请停止这样的提问,你能做的还有很多 names daily-life memory loss, difficulty with familiar tasks, word-finding, and changes in thought, attention, mood, or behavior.
• Diagnostic synthesis - VOL.133“____，您还记得我是谁吗？”请停止这样的提问,你能做的还有很多 separates simple screening from history, testing, exclusion, imaging, blood, and cerebrospinal-fluid assessment.
• Biomarker frame - VOL.133“____，您还记得我是谁吗？”请停止这样的提问,你能做的还有很多 discusses Aβ, tau, and neurodegeneration within an ATN-style account.
• Differential-diagnosis example - VOL.133“____，您还记得我是谁吗？”请停止这样的提问,你能做的还有很多 reports a family whose initial early-onset Alzheimer label was revised after vitamin B12 deficiency was identified and treated.

Counterevidence & Qualifications

The source is public education rather than a diagnostic guideline. It does not specify validated screening instruments, test thresholds, biomarker cutoffs, treatment eligibility, or a complete differential diagnosis. The B12 case is anecdotal and must not be generalized into supplementation or false reassurance.

What Changed

• Created a staged framework separating recognition, screening, differential diagnosis, biomarkers, and clinical diagnosis.

Related Concepts

• Medical Diagnostic Reasoning - broader process for combining history, tests, alternatives, and uncertainty.
• Diagnostic Safety Netting / 诊断安全网 - follow-up frame when symptoms or initial results remain uncertain.
• Cognitive Decline Advance Planning / 认知障碍提前规划 - planning opportunity created by earlier recognition while capacity remains.
• Amyloid Hypothesis Uncertainty - mechanism uncertainty that biomarkers alone do not eliminate.
• Alzheimer Drug Efficacy Gap - treatment-benefit and risk boundary relevant after diagnosis.
• Modifiable Dementia Risk Factors - prevention frame distinct from diagnosing current impairment.